George Laking
Medical Oncologist, Auckland









BIOGRAPHY

George is a medical oncologist in Auckland. Many years ago he was an internal medicine trainee in Wellington. In the interim he studied health economics and tumour physiology in London and Manchester. These days his practice is mainly in respiratory malignancy and sarcomas, including adolescent and young adult cancer.  Ki te taha a tona Māmā, he uri a Te Whakatōhea a Hōri.  George chairs the Māori Health Committee of the RACP, and is a member of its NZ Committee, and of the College Policy and Advocacy Council and its Advisory Committee. He chairs the College’s Working Party on Euthanasia and Physician Assisted Dying.  In his spare time he enjoys going out to see a band, and a long bike ride. 



ABSTRACT

Euthanasia And Physician Assist Dying

Euthanasia and Physician Assisted Dying (EPAD) is a live political topic in New Zealand and Australia.  The plus side is that it has got society to think and talk about death and dying.  The down side is that the conversations can be charged and divisive.  In New Zealand, the RACP’s NZ Committee recently submitted to the parliamentary inquiry of the Health Select Committee.  We made three main points: (1) it is complex, (2) it is a topic of significant importance to physicians caring for their patients, and (3) physicians need to be involved in any developments.  At the trans-Tasman level, the College set up a Working Party to clarify its position.  Although mindful of strong views in either direction, there is an over-riding awareness of the need to contribute to informed and respectful dialogue.  How should physicians respond to externally-driven change in their ethical working environment?  How should physicians respond in the event that EPAD becomes legislated?  This presentation will update on the Working Party’s thinking and progress.   


Update On Electronic Cigarettes

The modern electronic cigarette was patented by Chinese pharmacist Hon Lik in 2003, to start with as a personal effort to stop smoking. It consists of three main parts: a battery, a vaporiser, and a cartridge. The cartridge is loaded with “e-liquid”, that is aerosolised and inhaled. E-liquids are composed of propylene glycol, glycerol, and optionally, nicotine and flavourings. The practice of “vaping” has developed a profitable global following. Sales exceeded $6Bn US in 2015 — still less than 1% of total tobacco sales, but expected to reach $32Bn by 2021. The e-cigarette is a topic of controversy in public health. Opponents perceive a threat to the tobacco endgame, and an attempt by the tobacco industry to re-mormalise smoking and recruit a new generation of nicotine addicts. Supporters perceive a possible safe and effective new form of inhaled nicotine replacement, and appeal to civil liberties. Evidence on the risks and benefits has lagged behind opinion. It seems the e-cigarette has to some extent fractured an alliance between those more opposed to the addictive nature of tobacco smoking in populations, and those more concerned with its effects on the health of individuals. This presentation will review the current and future status of e-cigarette technology and regulation.